PCI acquires Bellwyck Pharma Services

By Jenni Spinner

- Last updated on GMT

(Image: Getty/Manop1984)
(Image: Getty/Manop1984)

Related tags: Pci pharma services, Bellwyck Pharma Services, primary packaging, Secondary packaging

The purchase follows PCI’s plans to expand its clinical trial services globally, including in North America and Europe.

Headquartered in Toronto, Canada, Bellwyck focuses on primary and secondary packaging and labeling for the clinical trial and commercial drug markets. Its acquisition expands PCI Pharma Services’ network of good manufacturing practice (GMP)-compliant facilities by four.

Salim Haffar, PCI’s CEO, told Outsourcing-Pharma that the company’s recent string of acquisitions fits its goal to expand its global presence and provide greater access for customers.

Our recent acquisitions align with our purpose to be the bridge between life-changing therapies and patients around the world, helping us achieve greater access around the world for our clients.

“With the addition of Bellwyck, PCI has now established a presence in Canada and Germany, ranked third and fourth in the world for total number of clinical trials, respectively, extending the reach of PCI’s clinical services in key markets,” he said.

The clinical and commercial supply chain solutions offered by Bellwyck support PCI’s core capabilities, such as clinical trial packaging, labeling and logistics for Phase I-IV studies, and full-service commercial packaging, the company stated. The acquisition brings the number of PCI’s GMP-compliant facilities to 25 and increases its total workforce in North America, Europe and the Asia-Pacific region to more than 3,700.

The addition of Bellwyck will mark PCI’s third acquisition outside of the US in three years, demonstrating its focus on geographic expansion.

The company in August 2019 announced plans to construct a 75,000-square-foot dedicated clinical facility outside of Dublin​, Ireland. Additionally, in February 2018, the company declared its intentions to snap up Melbourne, Australia-based Pharmaceutical Packaging Professionals​.

Haffar told Outsourcing-Pharma that PCI continues to hunt for strategic acquisitions around the globe.

We are always on the lookout for partnerships that complement our capabilities and allow us to enter new markets; we will continue our strategy to ensure we are servicing our clients and the patients they serve in the best way possible,” he said.

Related news

Show more

Related products

show more

What should a clinical metadata repository do?

What should a clinical metadata repository do?

Formedix | 26-Jul-2021 | Technical / White Paper

Choosing a clinical metadata repository (MDR) software can be a tough task as the capabilities and features of your chosen MDR could make or break your...

Adapting supply chains to new ways of working

Adapting supply chains to new ways of working

World Courier | 15-Jul-2021 | Technical / White Paper

COVID-19 has changed the way we operate. We have adapted our supply chain solutions to meet our clients’ requirements while following World Courier standard...

Empowering Clinical Trial Sponsors with Analytics

Empowering Clinical Trial Sponsors with Analytics

PerkinElmer | 14-Jul-2021 | Technical / White Paper

Is your Clinical Data Review creating problems or solving them? Take Control of Your Data. PerkinElmer Informatics Clinical Solutions, powered by Tibco...

What are the building blocks of DCTs?

What are the building blocks of DCTs?

Medable | 26-Apr-2021 | Technical / White Paper

How to create a seamless experience across eConsent, eCOA and more.

Over the past year, tremendous progress was made toward digitizing and...

Related suppliers

Follow us

Products

View more

Webinars